Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Marvel Biosciences Corp (TSE:MRVL)
TSXV:MRVL
RESEARCH TOOLSreports
Marvel Biosciences Corp (MRVL) Stock Price & Analysis
10 Followers
MRVL Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$0.01 - C$0.19
Previous CloseC$0.13
Volume189.50K
Average Volume (3M)46.46K
Market Cap
C$4.76M
Enterprise ValueC$6.04M
Total Cash (Recent Filing)C$217.69K
Total Debt (Recent Filing)C$1.50M
Price to Earnings (P/E)―
Beta-0.56
Next Earnings
Nov 20, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding39,786,231
10 Day Avg. Volume32,900
30 Day Avg. Volume46,460
Standard Deviation0.19
R-Squared0.00937
Alpha0.00166
Financial Highlights & Ratios
Price to Book (P/B)-1.78
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Marvel Biosciences Corp News
PremiumCompany Announcements
Marvel Biosciences Grants Stock Options to Leadership
PremiumCompany Announcements
Marvel Biosciences Expands Rett Syndrome Drug Research
PremiumCompany Announcements
Marvel Biosciences Raises Funds for Biomedical Research
PremiumCompany Announcements
Marvel Biosciences Targets Alzheimer’s with New Study Insights
PremiumCompany Announcements
Marvel Biosciences Secures Offering Extension
PremiumCompany Announcements
Marvel Biosciences Launches $1M Private PlacementPremiumCompany Announcements
Marvel Biosciences’ MB-204 Shows Promise Against NeurodegenerationPremiumCompany Announcements
Marvel Biosciences Unveils Hopeful Autism TherapyOptions Prices
Currently, No data available
---
Ownership Overview
19.20% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
80.80% Public Companies and
Individual Investors
MRVL FAQ
What was Marvel Biosciences Corp’s price range in the past 12 months?
Marvel Biosciences Corp lowest stock price was C$0.01 and its highest was C$0.19 in the past 12 months.
What is Marvel Biosciences Corp’s market cap?
Currently, no data Available
When is Marvel Biosciences Corp’s upcoming earnings report date?
Marvel Biosciences Corp’s upcoming earnings report date is Nov 20, 2024 which is in 116 days.
How were Marvel Biosciences Corp’s earnings last quarter?
Marvel Biosciences Corp released its earnings results on Jun 18, 2024. The company reported -C$0.008 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.008.
Is Marvel Biosciences Corp overvalued?
According to Wall Street analysts Marvel Biosciences Corp’s price is currently Overvalued.
Does Marvel Biosciences Corp pay dividends?
Marvel Biosciences Corp does not currently pay dividends.
What is Marvel Biosciences Corp’s EPS estimate?
Marvel Biosciences Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Marvel Biosciences Corp have?
Marvel Biosciences Corp has 38,053,720 shares outstanding.
What happened to Marvel Biosciences Corp’s price movement after its last earnings report?
Marvel Biosciences Corp reported an EPS of -C$0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.333%.
Which hedge fund is a major shareholder of Marvel Biosciences Corp?
Currently, no hedge funds are holding shares in TSE:MRVL
---
Marvel Biosciences Corp Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.25%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-71.54%
Trailing 12-Months
Company Description
Marvel Biosciences Corp
Alphanco Venture Corp is a capital pool company based in Canada. It proposes to identify and evaluate corporations, businesses or assets for acquisition and once identified and evaluated to negotiate an acquisition or participation subject to receipt of regulatory and shareholder approval, as applicable.
---
Technical Analysis
---